期刊文献+

衰老的骨髓间充质干细胞生物学行为及其意义

The biological behavior and significance of aging bone mesenchymal stem cells
原文传递
导出
摘要 骨髓间充质干细胞(BMSCs)是骨髓中除造血干细胞外的另一类具有高度可塑性的细胞群体,可从体内器官组织中分离出且具备在体外培养、诱导和扩增等特性,其在基因治疗、细胞治疗及组织工程等领域具有广泛的临床应用前景.近年来,BMSCs被越来越多地应用于自体移植进行细胞治疗和组织工程中,但是并不是所有的BMSCs都适用于自体移植.BMSCs会出现生物衰老,生物衰老的BMSCs分为年龄所致衰老和连续传代所致衰老.衰老的BMSCs因其生物学行为发生改变,其自体移植的成功率也随之降低.结合近年来有关BMSCs的研究进展,对衰老的BMSCs的生物学行为进行综述. Bone marrow mesenchymal stem cells (BMSCs),which can be isolated from organs and tissues,are cell populations with high degree of plasticity,similar to hematopoietic stem cells in bone marrow,and can be in vitro cultured,induced and amplified.BMSCs are increasingly used in gene therapy,cell therapy and tissue engineering.BMSCs have been currently studied in a number of autologous transplantations,while not all BMSCs are suitable for autologous transplantation.BMSCs exhibit biological aging gradually when cultured in vitro.Biological aging can be divided into age-induced senescence and long-term passage induced senescence.Aging BMSCs demonstrate changes in biological behaviour which reduces the success rate of autologous transplantation.In this review,biological aging BMSCs are discussed in order to provide help for the transplantation of BMSCs.
出处 《国际生物医学工程杂志》 CAS 2015年第1期63-64,I0001,I0002,共4页 International Journal of Biomedical Engineering
基金 国家自然科学基金资助项目(81071114,81371385)
关键词 骨髓间充质干细胞 微小RNA 生物学行为 Bone mesenchymal stem cells microRNAs Biological behaviour
  • 相关文献

参考文献41

  • 1Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells[J]. J Cell Physiol, 2007, 211(1): 27-35.
  • 2Kolf CM, Cho E, Tuan RS. Mesenchymal stromal ceils. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation[J]. Arthritis Res Ther, 2007, 9(1): 204.
  • 3Kilpinen L, Tigistu-Sahle F, Oja S, et al. Aging bone marrow mes- enchymal stromal cells have altered membrane glycerophospholipid composition and functionality[J]. J Lipid Res, 2013, 54(3): 622-635.
  • 4Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoi- etic stem-cell transplantation[J]. Blood, 2007, 110(7): 2764-2767.
  • 5Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells[J]. Leukemia, 2007, 21(8): 1733-1738.
  • 6Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study[J]. Lancet, 2008, 371(9624): 1579-1586.
  • 7Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility[J]. Clin J Am Soc Nephrol, 2011, 6(2): 412-422.
  • 8Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction[J]. J Am Coll Cardiol, 2009, 54(24): 2277-2286.
  • 9Asahara T, Kalka C, Isner JM. Stem cell therapy and gene transfer for regeneration[J]. Gene Ther, 2000, 7(6): 451-457.
  • 10Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study[J]. Lancet Neurol, 2012, 11(2): 150-156.

二级参考文献3

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部